“First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience”, Mediterr J Hematol Infect Dis, vol. 18, no. 1, p. e2026066, Sep. 2026, doi: 10.4084/MJHID.2026.066.